Who Paid My Doc
Michael Rickels
Endocrinology, Diabetes & Metabolism Philadelphia, PA Medical Doctor
NPI 1346272630 CMS profile 333447
3400 Spruce Street, 4 Penn Tower, Philadelphia, PA 19104
General payments
$65,295
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$540,438
Through program year 2025, Michael Rickels of Philadelphia, PA is reported in the CMS Open Payments database as having received $65,295 across 53 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $540,438 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 91st percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $23,650 | 15 | |
| 2024 | General | $10,851 | 8 | |
| 2023 | General | $11,209 | 8 | |
| 2022 | General | $9,883 | 11 | |
| 2021 | General | $4,827 | 9 | |
| 2020 | General | $4,875 | 2 |
Beside peers
- Michael Rickels
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Michael Rickels were reported at $23,650. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Michael Rickels | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $494 | $123–$2,253 | $163 |
| 2020 | $4,875 | $335 | $85–$1,841 | $114 |
| 2021 | $4,827 | $398 | $88–$1,981 | $132 |
| 2022 | $9,883 | $364 | $88–$1,568 | $149 |
| 2023 | $11,209 | $420 | $113–$1,614 | $160 |
| 2024 | $10,851 | $440 | $121–$1,646 | $164 |
| 2025 | $23,650 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
214
Drug cost
$61,205
Branded share of claims
54.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 35 | $52,204 | |
| Novolog Flexpen Insulin Aspart | Brand | 19 | $3,588 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 19 | $2,150 | |
| Metformin Hcl Er Metformin Hcl | Brand | 30 | $898 | |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | Brand | 14 | $656 | |
| Ezetimibe | Generic | 12 | $637 | |
| Atorvastatin Calcium | Generic | 23 | $433 | |
| Gabapentin | Generic | 13 | $247 | |
| Rosuvastatin Calcium | Generic | 11 | $186 | |
| Levothyroxine Sodium | Generic | 19 | $152 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 8 billing codesPaid by Medicare
$7,137
Medicare patients
46
Services billed
111
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Diabetes | 75% | |
| High blood pressure | 75% | |
| Chronic kidney disease | 59% | |
| Ischemic heart disease | 41% | |
| Arthritis | 37% | |
| Atrial fibrillation | 30% | |
| Heart failure | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
53 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Pennsylvania
Serge Jabbour
Endocrinology, Diabetes & Metabolism · Philadelphia, PA
Vijay Bahl
Endocrinology, Diabetes & Metabolism · Pittsburgh, PA
Geraldo Saavedra
Endocrinology, Diabetes & Metabolism · Whitehall, PA
Jane Mayrin
Endocrinology, Diabetes & Metabolism · Philadelphia, PA
Stephan Kowalyk
Endocrinology, Diabetes & Metabolism · Greensburg, PA
Matthew Kane
Endocrinology, Diabetes & Metabolism · West Chester, PA
Related records
Endocrinology, Diabetes & Metabolism in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.